返回搜索
正在招募II 期编号 NCT06065046

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

报名条件(概要)

  • 年龄:18 Years – 80 Years
  • 性别:不限
  • 健康志愿者:不接受

完整入排标准请以官方页面为准。

开展国家/地区

China

药品与企业信息

Baricitinib 4 MG药物

其他名称:Baricitinib

Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days

Standard treatment其他

其他名称:Blank control

Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.

研发企业

Tang-Du Hospital研究机构/其他

试验官方登记的主要申办方;研究机构申办时会显示相应机构名称。

生产企业

公开药品批准资料或正式说明书暂未提供明确的生产企业信息。

合作机构

  • Qianxian People's HospitalUNKNOWN
  • Weinan Central Hospital研究机构/其他
  • Second Affiliated Hospital of Xi'an Jiaotong University研究机构/其他
  • The First Hospital of YulinUNKNOWN
  • Xidian Group HospitalUNKNOWN
  • Chongqing Emergency Medical Center研究机构/其他
  • The Peoples' Hospital of Jiaozuo City研究机构/其他
  • First People's Hospital of Xianyang研究机构/其他
  • 987th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force研究机构/其他
  • Chongqing Hospital of PAPUNKNOWN
  • Baoji Fengxiang District HospitalUNKNOWN
  • GEM Flower Xian Changqing Staff HospitalUNKNOWN

研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业;生产企业仅取自美国上市原研药说明书所列企业(不含仿制药),不作推测;仅在其他国家上市的药品暂无法显示。

研究简介(原文)

The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.

适应症

Traumatic Brain Injury

主动联系研究团队

总联系人(申办方/研究总部)

中国/港澳台研究中心

问自己是否符合条件、如何预筛

我的病情档案

管理档案

档案只保存在您自己的浏览器里,不会上传,任何人(包括本站)都看不到。

英文版(发给研究团队)

Dear Study Team,

I am a patient in China and I am interested in participating in your clinical trial:

Study Title: Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
ClinicalTrials.gov Identifier: NCT06065046
Sponsor: Tang-Du Hospital
Investigational product: Baricitinib 4 MG, Standard treatment

About me:
- Age: (please fill in)
- Sex: (please fill in)
- Confirmed diagnosis and stage: (please fill in)
- Biomarkers / genetic testing: not available
- Prior and current treatments: (please fill in)
- Performance status (ECOG): not assessed
- Current location: China
- Travel ability: (please fill in)

Could you please let me know:
1. Whether I might be eligible for this study;
2. Which site would be closest and most practical for me, and whether remote pre-screening is possible;
3. What documents (medical records, pathology or imaging reports, recent labs) I should prepare for pre-screening.

I can provide English translations of my medical records. Thank you very much for your time and help.

Kind regards,
(your name)
(your email / phone with country code)

中文对照(供您核对)

尊敬的研究团队:

我是一位来自中国的患者,希望咨询参加以下临床试验的可能:

研究名称:Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
试验编号:NCT06065046
申办方:Tang-Du Hospital
研究药物:Baricitinib 4 MG、Standard treatment

我的基本情况:
- 年龄:(请填写)
- 性别:(请填写)
- 确诊疾病与分期:(请填写)
- 基因/标志物检测:暂无
- 既往及当前治疗:(请填写)
- 体能状态(ECOG):未评估
- 目前所在城市:中国
- 可前往范围:(请填写)

想请教三个问题:
1. 我是否可能符合本研究的入组标准?
2. 哪个中心对我最方便可行?能否远程预筛?
3. 预筛需要准备哪些资料(病历、病理、影像、近期化验)?

我可以提供英文翻译版病历。感谢您的时间与帮助。

顺祝安康
(您的姓名)
(您的邮箱/带国际区号的电话)
用邮件客户端发送给 gesn8561@fmmu.edu.cn

提示:请与主治医生一起发信——由医生署名的申请,回复率远高于患者单独发信。首封邮件不要附身份证号等敏感信息。研究团队通常在 3–10 个工作日内回复,两周无回音可礼貌追问一次。

下一步怎么做?

  1. 把本页信息带给您的主治医生,评估是否适合参加。
  2. 点击下方按钮打开官方注册页,查看研究中心联系方式。
  3. 直接联系研究团队咨询报名事宜(通常有中文同声翻译服务可协助沟通)。
在 ClinicalTrials.gov 查看官方页面